Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities
PR Newswire•30/10/2026•08:00 ET
1
Key Highlights
- ➤Azenta (AZTA) signs exclusive licensing agreement with Elegen for cell-free DNA synthesis technology
- ➤Azenta acquires SynPlexity, adding pooled assembly technology for thousands of full-length gene variants
- ➤Elegen platform targets improved DNA quality, delivery speed, and manufacturing scalability
- ➤SynPlexity capabilities expand high-throughput screening for synthetic biology and AI-generated designs
Expert Statements
Trey Martin, President, Multiomics at Azenta
“These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth”
Trey Martin, President, Multiomics at Azenta
“By combining these advanced technologies with our global infrastructure and existing gene-to-antibody portfolio, we are building a differentiated platform poised to accelerate the next era of biologics discovery and development.”
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities PR Newswire
Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GENEWIZ for long-term growth
Get started
Create a free account to read the full story.